Phastar Net-Zero Target Approved by the Science Based Targets Initiative
Phastar has had its net-zero target approved by the Science Based Targets initiative (SBTi). The SBTi is a global body enabling businesses to set ambitious emissions reductions targets in line with the latest climate science and is considered the gold standard for net-zero.
A component of Phastar’s commitment to SBTi is the pledge to achieve the Science Based Targets initiative (SBTi) Net-Zero Standard by 2035. By adopting stringent sustainability standards, Phastar aims to reduce its carbon footprint, engage with stakeholders, and promote responsible business practices.
In a press release, Phastar Chief Executive Officer Graham Clark said: “Having our net-zero target approved by the SBTi underscores our commitment to corporate responsibility and sustainable business practices. As a company, we pride ourselves on our mission to make a meaningful difference in the world, and on being a great company to work with and work for."
Phastar has already taken steps to hit net zero by 2035. Measures taken so far include strengthening the company’s emissions-measurement processes to enable more easy tracking. The organization has also developed and launched a sustainability strategy to outline exactly how it will reduce its emissions, as well as help its suppliers to do the same. Phastar also plans to roll out policies, initiatives, and incentives throughout its global team to help it become a more environmentally friendly business.
Clark continued, “Our net-zero by 2035 target is well ahead of industry norms and demonstrates Phastar’s dedication to reducing our carbon emissions. No one organization can tackle climate change alone, meaning we all must work together if we are to succeed. During our work so far, we have been extremely encouraged to find that many of our partners and clients already share our business values in this regard. We believe this will, ultimately, drive faster change."
Reference
Phastar Net-Zero Target Approved by the Science Based Targets Initiative. (2023, October 4). Phastar.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
